 Janelle Noel-MacDonnell
Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DiGeorge Syndrome | 4 | 2023 | 8 | 1.500 |
Why?
| | Bronchopulmonary Dysplasia | 5 | 2023 | 40 | 0.910 |
Why?
| | Humans | 41 | 2024 | 6896 | 0.910 |
Why?
| | Retrospective Studies | 22 | 2024 | 1296 | 0.890 |
Why?
| | Hypocalcemia | 1 | 2022 | 4 | 0.860 |
Why?
| | Tracheostomy | 5 | 2023 | 13 | 0.850 |
Why?
| | Models, Genetic | 1 | 2018 | 33 | 0.610 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 26 | 0.610 |
Why?
| | Female | 20 | 2024 | 3525 | 0.580 |
Why?
| | Child | 15 | 2024 | 3364 | 0.480 |
Why?
| | Infant | 12 | 2024 | 1446 | 0.430 |
Why?
| | Infant, Newborn | 11 | 2024 | 816 | 0.430 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2023 | 23 | 0.420 |
Why?
| | Male | 16 | 2024 | 3337 | 0.420 |
Why?
| | Substance-Related Disorders | 2 | 2023 | 26 | 0.400 |
Why?
| | Risk Factors | 9 | 2024 | 487 | 0.370 |
Why?
| | Lung Diseases | 2 | 2021 | 23 | 0.370 |
Why?
| | Genetic Testing | 2 | 2021 | 87 | 0.340 |
Why?
| | Lung | 2 | 2020 | 65 | 0.340 |
Why?
| | Child, Preschool | 8 | 2024 | 1569 | 0.270 |
Why?
| | Electronic Health Records | 3 | 2024 | 64 | 0.270 |
Why?
| | Calcium | 2 | 2023 | 41 | 0.270 |
Why?
| | Contraception | 2 | 2023 | 30 | 0.270 |
Why?
| | Exercise | 2 | 2024 | 140 | 0.250 |
Why?
| | Fibrinolytic Agents | 1 | 2024 | 8 | 0.240 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2024 | 20 | 0.240 |
Why?
| | Empyema, Pleural | 1 | 2024 | 13 | 0.240 |
Why?
| | Respiration, Artificial | 2 | 2022 | 17 | 0.240 |
Why?
| | Child Development | 2 | 2023 | 44 | 0.240 |
Why?
| | Cluster Analysis | 3 | 2019 | 43 | 0.230 |
Why?
| | Shock | 1 | 2024 | 4 | 0.230 |
Why?
| | Cognition | 2 | 2023 | 32 | 0.230 |
Why?
| | Wounds and Injuries | 1 | 2024 | 38 | 0.220 |
Why?
| | Gastric Bypass | 1 | 2023 | 8 | 0.220 |
Why?
| | Sleep Apnea Syndromes | 1 | 2023 | 9 | 0.220 |
Why?
| | Heart Ventricles | 1 | 2023 | 49 | 0.220 |
Why?
| | Pregnancy in Adolescence | 1 | 2023 | 9 | 0.220 |
Why?
| | Intrauterine Devices | 1 | 2023 | 4 | 0.220 |
Why?
| | Health Education | 1 | 2023 | 26 | 0.220 |
Why?
| | Tonsillectomy | 1 | 2022 | 11 | 0.210 |
Why?
| | Risk Assessment | 2 | 2020 | 137 | 0.210 |
Why?
| | Lymphopenia | 1 | 2022 | 1 | 0.210 |
Why?
| | Gastrostomy | 1 | 2023 | 63 | 0.210 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 48 | 0.210 |
Why?
| | Treatment Outcome | 5 | 2024 | 622 | 0.210 |
Why?
| | Cardiac Surgical Procedures | 1 | 2022 | 30 | 0.210 |
Why?
| | Transcriptome | 2 | 2022 | 59 | 0.210 |
Why?
| | Rhinitis | 1 | 2022 | 3 | 0.200 |
Why?
| | Sinusitis | 1 | 2022 | 5 | 0.200 |
Why?
| | Parents | 2 | 2023 | 157 | 0.200 |
Why?
| | Anesthesia | 1 | 2021 | 3 | 0.200 |
Why?
| | Mediastinal Neoplasms | 1 | 2021 | 5 | 0.200 |
Why?
| | Muscle Hypotonia | 1 | 2021 | 7 | 0.200 |
Why?
| | Nose Diseases | 1 | 2021 | 1 | 0.190 |
Why?
| | Velopharyngeal Insufficiency | 1 | 2021 | 1 | 0.190 |
Why?
| | Voice Disorders | 1 | 2021 | 1 | 0.190 |
Why?
| | Kidney Transplantation | 1 | 2022 | 115 | 0.190 |
Why?
| | Genetic Association Studies | 1 | 2021 | 53 | 0.190 |
Why?
| | Atrial Flutter | 1 | 2021 | 1 | 0.190 |
Why?
| | Cleft Palate | 1 | 2021 | 10 | 0.190 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2022 | 67 | 0.190 |
Why?
| | Leukemia | 1 | 2021 | 15 | 0.190 |
Why?
| | Neurotoxins | 1 | 2021 | 4 | 0.190 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2021 | 20 | 0.190 |
Why?
| | Ear, Inner | 1 | 2020 | 1 | 0.190 |
Why?
| | Labyrinth Diseases | 1 | 2020 | 1 | 0.190 |
Why?
| | Anatomic Variation | 1 | 2020 | 1 | 0.190 |
Why?
| | Hearing Loss | 1 | 2020 | 4 | 0.190 |
Why?
| | Temporal Bone | 1 | 2020 | 3 | 0.190 |
Why?
| | Diverticulum | 1 | 2020 | 4 | 0.190 |
Why?
| | Adolescent | 6 | 2024 | 2197 | 0.190 |
Why?
| | Botulinum Toxins | 1 | 2021 | 8 | 0.190 |
Why?
| | Environment Design | 1 | 2021 | 16 | 0.190 |
Why?
| | Adult | 5 | 2023 | 1181 | 0.190 |
Why?
| | Infant, Premature | 4 | 2023 | 85 | 0.180 |
Why?
| | Enterocolitis | 1 | 2021 | 34 | 0.180 |
Why?
| | Neonatal Nursing | 1 | 2020 | 2 | 0.180 |
Why?
| | Chorioamnionitis | 1 | 2020 | 4 | 0.180 |
Why?
| | Hirschsprung Disease | 1 | 2021 | 52 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 231 | 0.170 |
Why?
| | Language Development | 1 | 2019 | 5 | 0.170 |
Why?
| | Simulation Training | 1 | 2019 | 1 | 0.170 |
Why?
| | Waiting Lists | 1 | 2019 | 12 | 0.170 |
Why?
| | Conscious Sedation | 1 | 2019 | 2 | 0.170 |
Why?
| | Neonatology | 1 | 2019 | 5 | 0.170 |
Why?
| | Professional-Family Relations | 1 | 2019 | 10 | 0.170 |
Why?
| | Echocardiography | 1 | 2020 | 81 | 0.170 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2019 | 3 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 14 | 0.170 |
Why?
| | Appointments and Schedules | 1 | 2019 | 12 | 0.170 |
Why?
| | Toll-Like Receptor 4 | 1 | 2019 | 11 | 0.170 |
Why?
| | Postoperative Complications | 1 | 2021 | 184 | 0.170 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 108 | 0.170 |
Why?
| | Communication | 1 | 2019 | 46 | 0.170 |
Why?
| | Heart Defects, Congenital | 1 | 2020 | 81 | 0.170 |
Why?
| | Crowdsourcing | 1 | 2019 | 1 | 0.170 |
Why?
| | Normal Distribution | 1 | 2018 | 4 | 0.160 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 65 | 0.160 |
Why?
| | Models, Statistical | 1 | 2018 | 29 | 0.160 |
Why?
| | Lipoprotein(a) | 1 | 2018 | 1 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 122 | 0.160 |
Why?
| | Cholesterol, HDL | 1 | 2018 | 10 | 0.160 |
Why?
| | Likelihood Functions | 1 | 2018 | 6 | 0.160 |
Why?
| | Health Behavior | 1 | 2018 | 50 | 0.150 |
Why?
| | Patient Compliance | 1 | 2018 | 55 | 0.150 |
Why?
| | Patient Readmission | 1 | 2018 | 68 | 0.150 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 243 | 0.140 |
Why?
| | Age Factors | 3 | 2024 | 210 | 0.140 |
Why?
| | Ovarian Neoplasms | 1 | 2018 | 136 | 0.140 |
Why?
| | Respiratory Tract Infections | 1 | 2018 | 85 | 0.140 |
Why?
| | Myositis, Inclusion Body | 1 | 2016 | 1 | 0.140 |
Why?
| | Homeostasis | 1 | 2016 | 8 | 0.140 |
Why?
| | Proteins | 1 | 2016 | 27 | 0.130 |
Why?
| | Pediatric Obesity | 1 | 2018 | 137 | 0.130 |
Why?
| | Intensive Care Units, Neonatal | 3 | 2021 | 38 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 336 | 0.120 |
Why?
| | Pregnancy | 2 | 2023 | 216 | 0.090 |
Why?
| | Young Adult | 2 | 2023 | 647 | 0.090 |
Why?
| | Gestational Age | 2 | 2020 | 62 | 0.080 |
Why?
| | Cohort Studies | 2 | 2021 | 289 | 0.080 |
Why?
| | Time Factors | 2 | 2020 | 250 | 0.080 |
Why?
| | Patient Discharge | 2 | 2021 | 57 | 0.080 |
Why?
| | Databases, Factual | 2 | 2019 | 108 | 0.080 |
Why?
| | Mutation | 2 | 2021 | 212 | 0.080 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 45 | 0.070 |
Why?
| | Mice | 2 | 2019 | 348 | 0.070 |
Why?
| | Animals | 2 | 2019 | 729 | 0.060 |
Why?
| | Thrombolytic Therapy | 1 | 2024 | 8 | 0.060 |
Why?
| | Drainage | 1 | 2024 | 36 | 0.060 |
Why?
| | Alanine Transaminase | 1 | 2024 | 10 | 0.060 |
Why?
| | Triglycerides | 1 | 2024 | 22 | 0.060 |
Why?
| | Vital Signs | 1 | 2024 | 3 | 0.060 |
Why?
| | ROC Curve | 1 | 2024 | 22 | 0.060 |
Why?
| | Blood Pressure | 1 | 2024 | 67 | 0.060 |
Why?
| | Hospital Mortality | 1 | 2024 | 22 | 0.060 |
Why?
| | Injury Severity Score | 1 | 2024 | 52 | 0.060 |
Why?
| | Dexamethasone | 1 | 2023 | 29 | 0.060 |
Why?
| | Neurodevelopmental Disorders | 1 | 2023 | 23 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2023 | 32 | 0.060 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 53 | 0.060 |
Why?
| | Ferritins | 1 | 2023 | 4 | 0.060 |
Why?
| | Polysomnography | 1 | 2023 | 14 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 37 | 0.060 |
Why?
| | Fluoroscopy | 1 | 2023 | 19 | 0.060 |
Why?
| | Radiography | 1 | 2023 | 37 | 0.060 |
Why?
| | Pregnancy, Unplanned | 1 | 2023 | 9 | 0.060 |
Why?
| | Patient-Centered Care | 1 | 2023 | 16 | 0.050 |
Why?
| | Program Evaluation | 1 | 2023 | 45 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2023 | 13 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2023 | 58 | 0.050 |
Why?
| | Adenoidectomy | 1 | 2022 | 10 | 0.050 |
Why?
| | Pilot Projects | 1 | 2023 | 120 | 0.050 |
Why?
| | Survival Rate | 1 | 2022 | 83 | 0.050 |
Why?
| | Retinoid X Receptors | 1 | 2022 | 3 | 0.050 |
Why?
| | Chromosomes | 1 | 2022 | 3 | 0.050 |
Why?
| | Systems Analysis | 1 | 2022 | 1 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2022 | 31 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 25 | 0.050 |
Why?
| | Health Expenditures | 1 | 2022 | 15 | 0.050 |
Why?
| | Medication Adherence | 1 | 2022 | 21 | 0.050 |
Why?
| | Enteral Nutrition | 1 | 2022 | 63 | 0.050 |
Why?
| | Fungi | 1 | 2022 | 20 | 0.050 |
Why?
| | Intubation, Intratracheal | 1 | 2021 | 3 | 0.050 |
Why?
| | Karyotyping | 1 | 2021 | 11 | 0.050 |
Why?
| | Amino Acid Substitution | 1 | 2021 | 12 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2021 | 47 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2022 | 215 | 0.050 |
Why?
| | Palate, Soft | 1 | 2021 | 1 | 0.050 |
Why?
| | Length of Stay | 1 | 2022 | 233 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2021 | 3 | 0.050 |
Why?
| | Standard of Care | 1 | 2021 | 5 | 0.050 |
Why?
| | Kansas | 1 | 2021 | 43 | 0.050 |
Why?
| | Cities | 1 | 2021 | 10 | 0.050 |
Why?
| | Audiometry | 1 | 2020 | 1 | 0.050 |
Why?
| | Recovery of Function | 1 | 2020 | 17 | 0.050 |
Why?
| | Chronic Disease | 1 | 2021 | 105 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2021 | 119 | 0.050 |
Why?
| | Infant, Extremely Premature | 1 | 2020 | 14 | 0.050 |
Why?
| | Incidence | 1 | 2021 | 133 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 99 | 0.050 |
Why?
| | Walking | 1 | 2021 | 34 | 0.050 |
Why?
| | Residence Characteristics | 1 | 2021 | 42 | 0.050 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 38 | 0.050 |
Why?
| | Diagnostic Errors | 1 | 2020 | 7 | 0.050 |
Why?
| | Phenotype | 1 | 2021 | 257 | 0.050 |
Why?
| | Weight Gain | 1 | 2020 | 23 | 0.050 |
Why?
| | Alleles | 1 | 2021 | 214 | 0.050 |
Why?
| | Prevalence | 1 | 2020 | 146 | 0.040 |
Why?
| | Hospitals, Pediatric | 1 | 2022 | 187 | 0.040 |
Why?
| | Pandemics | 1 | 2021 | 82 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 117 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 17 | 0.040 |
Why?
| | Genotype | 1 | 2021 | 410 | 0.040 |
Why?
| | Language Development Disorders | 1 | 2019 | 4 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2019 | 12 | 0.040 |
Why?
| | Self-Assessment | 1 | 2019 | 5 | 0.040 |
Why?
| | Attitude | 1 | 2019 | 10 | 0.040 |
Why?
| | Professional Competence | 1 | 2019 | 3 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 17 | 0.040 |
Why?
| | Family | 1 | 2019 | 27 | 0.040 |
Why?
| | Curriculum | 1 | 2019 | 22 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 20 | 0.040 |
Why?
| | Cytokines | 1 | 2019 | 48 | 0.040 |
Why?
| | Ireland | 1 | 2019 | 1 | 0.040 |
Why?
| | Italy | 1 | 2019 | 3 | 0.040 |
Why?
| | Organizations, Nonprofit | 1 | 2019 | 3 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2019 | 25 | 0.040 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2019 | 3 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2019 | 39 | 0.040 |
Why?
| | Pneumonia | 1 | 2019 | 32 | 0.040 |
Why?
| | Machine Learning | 1 | 2019 | 17 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 41 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 150 | 0.040 |
Why?
| | Protective Factors | 1 | 2018 | 8 | 0.040 |
Why?
| | Atherosclerosis | 1 | 2018 | 2 | 0.040 |
Why?
| | Pulse Wave Analysis | 1 | 2018 | 4 | 0.040 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 6 | 0.040 |
Why?
| | Positive-Pressure Respiration | 1 | 2018 | 1 | 0.040 |
Why?
| | Signal Transduction | 1 | 2019 | 132 | 0.040 |
Why?
| | Oxygen | 1 | 2018 | 14 | 0.040 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2018 | 10 | 0.040 |
Why?
| | Self Report | 1 | 2018 | 42 | 0.040 |
Why?
| | Dyslipidemias | 1 | 2018 | 15 | 0.040 |
Why?
| | Logistic Models | 1 | 2018 | 84 | 0.040 |
Why?
| | Algorithms | 1 | 2019 | 105 | 0.040 |
Why?
| | Primary Health Care | 1 | 2018 | 42 | 0.040 |
Why?
| | Missouri | 1 | 2018 | 81 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 274 | 0.040 |
Why?
| | Hypertension | 1 | 2018 | 66 | 0.040 |
Why?
| | United States | 1 | 2020 | 669 | 0.040 |
Why?
| | Hydroxylamines | 1 | 2016 | 1 | 0.030 |
Why?
| | Myoblasts | 1 | 2016 | 2 | 0.030 |
Why?
| | Muscle Contraction | 1 | 2016 | 3 | 0.030 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2016 | 2 | 0.030 |
Why?
| | Amyloid beta-Peptides | 1 | 2016 | 2 | 0.030 |
Why?
| | Muscle Strength | 1 | 2016 | 3 | 0.030 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 3 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2016 | 8 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2016 | 3 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 20 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 18 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2016 | 84 | 0.030 |
Why?
| | Rats | 1 | 2016 | 106 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|